Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 304 participants.
Also called NCT02407210
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 304 participants
- Registry
-
NCT02407210
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- Not reported
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02407210. Randomized; triple masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2015-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- azilsartan
- Intervention (Drug)
- Olmesartan medoxomil
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct02407210- Content hash
87bf86f3d7cd3fd6c8140fe10fe8e44e7e3992da322e5d1305cb9226a216e8e9